S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Italy's Meloni vows to put national energy interests first
Danes: Nord Stream 2 pipeline seems to have stopped leaking
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Italy's Meloni vows to put national energy interests first
Danes: Nord Stream 2 pipeline seems to have stopped leaking
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Italy's Meloni vows to put national energy interests first
Danes: Nord Stream 2 pipeline seems to have stopped leaking
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia blindfolds, detains Ukraine nuclear plant chief
Ruptured oil pipeline off California approved for repairs
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Italy's Meloni vows to put national energy interests first
Danes: Nord Stream 2 pipeline seems to have stopped leaking

Innate Pharma - IPHA Stock Forecast, Price & News

$2.00
-0.07 (-3.38%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.98
$2.10
50-Day Range
$2.00
$3.20
52-Week Range
$1.98
$6.50
Volume
14,822 shs
Average Volume
12,293 shs
Market Capitalization
$159.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.15

Innate Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
357.5% Upside
$9.15 Price Target
Short Interest
Bearish
0.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.88mentions of Innate Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.42) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

923rd out of 1,095 stocks

Biological Products, Except Diagnostic Industry

150th out of 171 stocks

IPHA stock logo

About Innate Pharma (NASDAQ:IPHA) Stock

Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.

Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

IPHA Stock News Headlines

Innate Pharma Turns To Profit In H1
Innate Pharma reports Q1 results
Innate Pharma S.A. ADS (IPHA)
See More Headlines
Receive IPHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

IPHA Company Calendar

Today
10/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IPHA
Fax
N/A
Employees
215
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.15
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.10
Forecasted Upside/Downside
+357.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$29.23 million
Book Value
$1.60 per share

Miscellaneous

Free Float
54,303,000
Market Cap
$159.46 million
Optionable
Not Optionable
Beta
0.56

Key Executives

  • Dr. Mondher Mahjoubi M.D. (Age 64)
    Chairman of Exec. Board & CEO
    Comp: $1.03M
  • Mr. Yannis Morel Ph.D. (Age 49)
    Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board
    Comp: $408.78k
  • Dr. Herve Brailly (Age 61)
    Co-Founder & Chairman of Supervisory Board
  • Dr. François Romagné Ph.D. (Age 58)
    Founder
  • Mr. Eric Vivier D.V.M. (Age 58)
    M.B.A., Ph.D., Founder, Sr. VP & Chief Scientific Officer
  • Dr. Marc Bonneville Ph.D. (Age 62)
    Founder
  • Mr. Jean Jacques Fournié Ph.D.
    Founder
  • Mr. Alessandro Moretta M.D.
    Ph.D., Founder
  • Mr. Frederic Lombard M.B.A. (Age 47)
    Sr. VP & CFO
  • Ms. Odile Belzunce (Age 42)
    VP of Compliance & Operations













IPHA Stock - Frequently Asked Questions

Should I buy or sell Innate Pharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IPHA shares.
View IPHA analyst ratings
or view top-rated stocks.

What is Innate Pharma's stock price forecast for 2022?

4 brokerages have issued 12 month price targets for Innate Pharma's stock. Their IPHA share price forecasts range from $3.10 to $12.00. On average, they anticipate the company's share price to reach $9.15 in the next twelve months. This suggests a possible upside of 357.5% from the stock's current price.
View analysts price targets for IPHA
or view top-rated stocks among Wall Street analysts.

How have IPHA shares performed in 2022?

Innate Pharma's stock was trading at $4.56 at the beginning of 2022. Since then, IPHA stock has decreased by 56.1% and is now trading at $2.00.
View the best growth stocks for 2022 here
.

What is Hervé Brailly's approval rating as Innate Pharma's CEO?

4 employees have rated Innate Pharma Chief Executive Officer Hervé Brailly on Glassdoor.com. Hervé Brailly has an approval rating of 100% among the company's employees. This puts Hervé Brailly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Innate Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innate Pharma investors own include Cidara Therapeutics (cdtx), VBI Vaccines (VBIV), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), INmune Bio (INMB), Pluristem Therapeutics (PSTI) and Sanofi (SNY).

When did Innate Pharma IPO?

(IPHA) raised $80 million in an IPO on Thursday, October 17th 2019. The company issued 10,700,000 shares at a price of $7.50 per share. Citigroup, SVB Leerink and Evercore ISI served as the underwriters for the IPO.

What is Innate Pharma's stock symbol?

Innate Pharma trades on the NASDAQ under the ticker symbol "IPHA."

How do I buy shares of Innate Pharma?

Shares of IPHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innate Pharma's stock price today?

One share of IPHA stock can currently be purchased for approximately $2.00.

How much money does Innate Pharma make?

Innate Pharma (NASDAQ:IPHA) has a market capitalization of $159.46 million and generates $29.23 million in revenue each year.

How many employees does Innate Pharma have?

The company employs 215 workers across the globe.

How can I contact Innate Pharma?

Innate Pharma's mailing address is 117 AVENUE DE LUMINY BP 30191, MARSEILLE I0, 13009. The official website for the company is www.innate-pharma.com. The company can be reached via phone at 33-4-30-30-30-30 or via email at investors@innate-pharma.com.

This page (NASDAQ:IPHA) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.